Clinical trials: Gout Arthritis
Gout
DECT Study in Allopurinol-Treated Gout Patients
The purpose of this study is to determine presence and volume of monosodium urate (MSU) crystal deposits as determined by dual-energy computed tomography (DECT) imaging in gout subjects treated with allopurinol with and without…
- Trial name
- NCT02393560
- Testing
- DECT scan
- Where
- 10 sites in United States, New Zealand
- Volunteers
- 223 people
- Sponsor
- Ardea Biosciences, Inc.
Hyperuricemia, Gout
Safety and Efficacy Study of MBX-102 in Treatment of Hyperuricemia in Patients With Gout
The purpose of the study is to evaluate the safety and effectiveness of MBX-102 compared to placebo when given orally once daily for 4 weeks for the treatment of hyperuricemia in patients with gout.
- Trial name
- NCT01336686
- Testing
- Arhalofenate, Colchicine
- Where
- 12 sites in United States
- Volunteers
- 67 people
- Sponsor
- Gilead Sciences
Gout
RDEA3170 PK/PD Study
The purpose of this study is to examine the pharmacokinetic and pharmacodynamic effect of RDEA3170 when given as single or multiple doses
- Trial name
- NCT02608710
- Testing
- RDEA3170 4.5 mg, RDEA3170 6 mg, RDEA3170 12 mg
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Ardea Biosciences, Inc.
Gout
A Study of AC-201 Controlled-Release Tablet (CR Tablet) in Patients With Gout
The study is designed to test the urate-lowering effect, safety, and tolerability of AC-201CR in an initial dosing period, followed by the addition of a ULT to test the efficacy and safety of the combination and prophylaxis of…
- Trial name
- NCT02287818
- Testing
- AC-201, Febuxostat
- Where
- Taiwan
- Volunteers
- 127 people
- Sponsor
- TWi Biotechnology, Inc.
Gout, Hyperuricemia
Open Label PK, PD and DDI of Dotinurad and Allopurinol in Gout Patients With Hyperuricemia
A open label multi-center 3-period multidose, PK/PD and drug-drug interaction (DDI) study to evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) of 7 days of treatment with two doses of dotinurad monotherapy, and to…
- Trial name
- NCT06056570
- Testing
- dotinurad, dotinurad + allopurinol, allopurinol
- Where
- 4 sites in United States
- Volunteers
- 20 people
- Sponsor
- Urica Therapeutics Inc.
Gout
Bucillamine for the Treatment of Acute Gout Flare in Subjects With Moderate to Severe Gout
A Phase IIA, open-label, multicenter, active-controlled, parallel-group clinical trial designed to evaluate the safety and efficacy of two doses of Bucillamine compared with low-dose Colchicine in the treatment of patients with…
- Trial name
- NCT02330796
- Testing
- Bucillamine, Colchicine
- Where
- 3 sites in United States
- Volunteers
- 66 people
- Sponsor
- Revive Therapeutics, Ltd.
Chronic Uncontrolled Gout, Gout
Infusion Duration Study To Assess Tolerability of Pegloticase Administered With a Shorter Infusion Duration in Subjects With Uncontrolled Gout Receiving Methotrexate
The purpose of this study is to assess the safety, tolerability and efficiency of pegloticase administered with a shorter infusion duration in participants with uncontrolled gout receiving methotrexate.
- Conditions
- Chronic Uncontrolled Gout, Gout, Uncontrolled Gout
- Trial name
- NCT04511702
- Testing
- Pegloticase with MTX
- Where
- 39 sites in United States
- Volunteers
- 191 people
- Sponsor
- Amgen
Gout
Study of the Safety and Effectiveness of Rilonacept for the Prevention of Gout Flares
This was a clinical research study to determine the safety and effectiveness of an experimental drug called rilonacept in participants with gout who were beginning another additional treatment.
- Trial name
- NCT00610363
- Testing
- Rilonacept
- Where
- 34 sites in United States
- Volunteers
- 83 people
- Sponsor
- Regeneron Pharmaceuticals
Hyperuricemia, Gout
Magnetic Resonance Imaging in Subjects With Gouty Tophi
The purpose of this study is to determine the reproducibility of Magnetic Resonance Imaging (MRI) in the quantitative assessment of tophus volume.
- Trial name
- NCT00174954
- Testing
- MRI
- Volunteers
- 32 people
- Sponsor
- Takeda
Gout, Hyperuricemia
Study of URC102 to Assess the Safety and Efficacy in Gout Patients
The purpose of this study is to assess safety, Pharmacokinetics/Pharmacodynamics and Urate Lowering Effect of URC102 in gout patients.
- Trial name
- NCT02557126
- Testing
- URC102
- Where
- South Korea
- Volunteers
- 76 people
- Sponsor
- JW Pharmaceutical
Gout
RDEA3170 Monotherapy in Subjects With Gout
This study will assess the serum uric acid lowering effects and safety of 3 dose levels of RDEA3170 compared to placebo in subjects with gout.
- Trial name
- NCT01927198
- Testing
- RDEA3170 5 mg, RDEA3170 10 mg, RDEA3170 12.5 mg
- Where
- 49 sites in United States
- Volunteers
- 172 people
- Sponsor
- Ardea Biosciences, Inc.
Hyperuricemia, Gout
Study 102: Multiple Ascending Dose Study of ALLN-346 (Engineered Urate Oxidase)
The purpose of this Phase I study is to evaluate the safety and tolerability of ALLN-346 in in normal healthy volunteers, in an ascending dose design.
- Trial name
- MAD (NCT04829435)
- Testing
- ALLN-346
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Allena Pharmaceuticals
Gout
A Study to Evaluate Safety and Efficacy of Oral Febuxostat in Patients With Gout
This is a multicenter, open label, randomized, allopurinol-controlled, parallel-design study. Approximately 120 subjects will be randomly assigned in 1:1 ratio to receive febuxostat, or allopurinol for subjects with gout.
- Trial name
- NCT01736514
- Testing
- febuxostat, Allopurinol
- Where
- 4 sites in Taiwan
- Volunteers
- 109 people
- Sponsor
- Astellas Pharma Taiwan, Inc.
Gout
Intensive Urate Lowering Therapy of Febuxostat Compared to Allopurinol on Cardiovascular Risk in Patients With Gout
There is a mounting and clear association between hyperuricaemia, gout and the presence of traditional cardiovascular (CV) risk factors and CV event-equivalent conditions such as chronic kidney disease, metabolic syndrome, and…
- Trial name
- FORWARD (NCT02500641)
- Testing
- Febuxostat 80/120mg/day, Allopurinol 100 up to 600mg/day, Colchicine
- Where
- 26 sites in Germany, Italy and 4 more
- Volunteers
- 196 people
- Sponsor
- Menarini International Operations Luxembourg SA
Acute Gouty Arthritis
A Study to Evaluate the Efficacy,Safety,Tolerability,Pharmacokinetics,and Immunogenicty of Plonmarlimab in Subjects With Acute Gouty Arthritis
This is a multi center,randomized,double-blind,double-dummy,active-controlled study,and planned enrollment of 120-170 subjects,an interim analysis will be conducted after first 60 subjects complete the 72 -hour pain Visual…
- Trial name
- NCT07453004
- Testing
- Plonmarlimab, Compound betamethasone
- Where
- 30 sites in China
- Volunteers
- 170 people
- Sponsor
- TJ Biopharma Co., Ltd.
Gout
Long-Term Safety of Febuxostat in Subjects With Gout.
The purpose of this study is to evaluate the long-term safety of febuxostat, once daily (QD), in maintaining serum urate levels within clinically acceptable levels in subjects with gout.
- Trial name
- FOCUS (NCT00174941)
- Testing
- Febuxostat
- Volunteers
- 116 people
- Sponsor
- Takeda
Gout
Safety and Pharmacodynamics of SEL-037 (Pegsiticase) in Subjects With Elevated Blood Uric Acid Levels
This Study will evaluate the safety, pharmacokinetics, pharmacodynamics and immunogenicity of a single intravenous infusion of SEL-037 (pegsiticase), a pegylated uricase, in subjects with elevated blood uric acid levels.
- Trial name
- NCT02464605
- Testing
- SEL-037 (pegsiticase)
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- Selecta Biosciences, Inc.
Osteoarthritis
Efficacy of Proprietary Cherry Juice Blend in Osteoarthritis of the Knee
The primary purpose of this research study is to test the ability of a proprietary cherry juice blend to be helpful in the treatment of osteoarthritis (OA) of the knee.
- Trial name
- NCT00443092
- Testing
- proprietary cherry juice blend (food), control juice (kool aid blend)
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- CherryPharm
Gout
Study of Safety, PK, and Efficacy of Multiple Ascending Doses of HZBio1 in Patients With Gout
Study YDHY (HZBio1)-001 (Ib/Ⅱ) is an open-label, dose-escalation and expansion, multicenter Phase Ib/II clinical trial conducted in China.
- Trial name
- NCT07752810
- Testing
- Phase 1b: HZBio1 3mg, Phase 1b: HZBio1 6mg, Phase 1b: HZBio1 12mg
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Hangzhou Grand Biologic Pharmaceutical, Inc.
Gout
Efficacy and Safety of Oral Febuxostat in Participants With Gout
The purpose of this study is to compare the efficacy and safety of febuxostat, once Daily (QD), to allopurinol in subjects with hyperuricemia and gout.
- Trial name
- CONFIRMS (NCT00430248)
- Testing
- Febuxostat, Allopurinol
- Where
- 258 sites in United States
- Volunteers
- 2,269 people
- Sponsor
- Takeda